Third Rock launches Tango Therapeutics | Chemical & Engineering News
Volume 95 Issue 14 | p. 18 | Concentrates
Issue Date: April 3, 2017

Third Rock launches Tango Therapeutics

Department: Business
Keywords: oncology, venture capital, CRISPR

The venture capital firm Third Rock Ventures has launched the cancer drug company Tango Therapeutics with $55 million in series A funding. Based in Cambridge, Mass., Tango says it will use DNA sequencing and CRISPR-enabled target discovery to exploit vulnerabilities created by loss of tumor suppressor gene function, an effect it calls synthetic lethality. One of Tango’s scientific founders is Alan Ashworth, whose work in synthetic lethality led to the discovery of small-molecule PARP inhibitors for ovarian cancer.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment